SCHEMBL2432930

SCHEMBL2432930

N#C[Zn]c1cccc(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.38
▸ MGLL Q99685 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ NFE2L2 Q16236 4/20 0.37
▸ CES2 O00748 1/20 0.34
▸ CES1 P23141 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ THPO P40225 1/20 0.33
▸ CHRM5 P08912 1/20 0.33
▸ GRM5 P41594 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ PMP22 Q01453 1/20 0.33
▸ ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL2430230 0.98 FAAH (0.37) FAAHMGLLACHENFE2L2CES2
SCHEMBL28156385 0.71 — —
SCHEMBL1256661 0.70 — —
SCHEMBL1257838 0.70 — —
Hydrochloric Acid SCHEMBL15771610 0.69 TSHR (0.39) CYP1A2
Bromide SCHEMBL15771478 0.69 TSHR (0.39) CYP1A2
Iodide SCHEMBL2216576 0.68 ACHE (0.41) FAAHMGLLACHENFE2L2CES2
Nitrogen SCHEMBL29165728 0.67 ACHE (0.55) FAAHMGLLACHENFE2L2CES2
SCHEMBL13329 0.66 — —
SCHEMBL29444147 0.65 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319426-A1 Substituted Isoindoles ASTRAZENECA AB (SE) 2011-12-29 — — US disclosed
US-8030500-B2 Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies ASTRAZENECA AB (SE) 2011-10-04 — — US disclosed
EP-2367814-A1 NEW COMPOUNDS 578 AstraZeneca AB (SE) 2011-09-28 — — EP disclosed
US-20100125082-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 — — US disclosed
WO-2010056196-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125082-A1 NEW COMPOUNDS 578 PSEN1, PSEN2, BACE1 FAAH 3282/4885MGLL 3751/4885ACHE 132/4885
US-20110319426-A1 Substituted Isoindoles PSEN2, PSEN1, SNCA FAAH 3230/4885MGLL 3797/4885ACHE 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback